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Atrial ﬁbrillation (AF) can be found in an increasing number of cardiac surgical patients due to a higher patient’s age and
comorbidities. Atrial ﬁbrillation is known, however, to be a risk factor for a greater mortality, and one aim of intraoperative
AF treatment is to approximate early and long-term survival of AF patients to survival of patients with preoperative sinus rhythm.
Today, surgeons are more and more able to perform less complex, that is, minimally invasive cardiac surgical procedures. The
evolution of alternative ablation technologies using diﬀerent energy sources has revolutionized the surgical therapy of atrial
ﬁbrillation and allows adding the ablation therapy without adding signiﬁcant risk. Thus, the surgical treatment of atrial ﬁbrillation
in combination with the cardiac surgery procedure allows to improve the postoperative long-term survival and to reduce
permanent anticoagulation in these patients. This paper focuses on the variety of incisions, lesion sets, and surgical techniques, as
well as energy modalities and results of AF ablation and also summarizes future trends and current devices in use.
1.Background
Atrial ﬁbrillation is deﬁned as uncontrolled atrial electrical
excitationata rateof >300 beatsperminute. The conduction
to the ventricles is irregular and in variable frequencies,
therefore resulting in the types of slow (bradycardiac),
normofrequent, or fast (tachycardiac) atrial ﬁbrillation (AF).
Furthermore, AF can be divided into paroxysmal, persistent,
and permanent (accepted) AF [1]. Paroxysmal AF is self-
terminating, usually within 48 hours. Although AF parox-
ysms may continue for up to 7 days, after 48 hours the likeli-
hood of spontaneous conversion is low, and anticoagulation
must be considered. Persistent AF is an AF episode which
either lasts longer than 7 days or requires termination by
cardioversionwithdrugsorbydirectelectricalcardioversion.
The persistent types of AF are frequently symptomatic and
are, depending on the comorbidities, associated with an
increased stroke risk. Persistent AF is added by the subtype
of long-standing persistent AF (>1y), when it is decided to
adopt a rhythm control strategy. Permanent AF is when the
presence of the arrhythmia is accepted and a rhythm control
is no longer pursued.
Surgical treatment of atrial ﬁbrillation should be consid-
eredasastand-aloneconceptwhenpatientsdonotgetfreeof
AF or symptoms despite multiple interventional ablations or
when a contraindication for catheter ablation exists [1]. Fur-
thermore, atrial ﬁbrillation as a comorbidity can be found
in an increasing number of cardiac surgical patients having
an indication for coronary artery bypass surgery and valve
surgery,respectively[2,3].Atrialﬁbrillationinthesepatients
is known to be a risk factor for mortality over the years
after the operation [4]. The surgical treatment of atrial
ﬁbrillation in combination with the core cardiac surgical
intervention has the aim to improve the postoperative long-
term survival of these patients and moreover to reduce the
likelihood of permanent anticoagulation. Recently, it has
been shown in a randomized trial that surgical ablation is
superior to catheter ablation in achieving freedom from left
atrial arrhythmias after 12 months of followup [5]. If there
are thrombus formations in the left atrial appendage (LAA),
or there is an increased risk of stroke, the simultaneous
intraoperative resection of the left auricle allows in analogy
to the data for the interventional atrial appendage closure a
reductionofembolicstrokerisk[6].Forsurgicaltreatmentof2 Cardiology Research and Practice
Figure 1: Port access for bilateral minimally invasive AF ablation. AF: atrial ﬁbrillation.
atrial ﬁbrillation today, in contrast to the widely established
surgical “cut and sew” technique established in the 1990s by
Jimmy Cox, almost always minimal-invasive ablation con-
cepts are applied. Doing so, it is possible to create an eﬀective
transmural lesion with low endothelial damage and without
adding a signiﬁcant risk to the cardiac procedure.
2. SurgicalTechniques for AF Ablation
For isolated treatment of atrial ﬁbrillation, there are diﬀerent
surgical approaches available today. Basically, they are now
performed endoscopically (Figure 1), whereupon depending
on the ablation concept mono- or bilateral thoracoscopic
approaches are possible. Because the ablation in this pathol-
ogy is predominantly performed epicardially, the procedure
is usually performed on the beating heart without using the
heart-lung machine. This minimal-invasive surgery allows
for short operation times of about 2hours, a rapid recovery,
and short hospital stay. Today, the Atricure system (Synergy
Ablation Clamp and Coolrail application, Atricure Inc., West
Chester, OH, USA) and the Estech device (Cobra adhere
XL, San Ramon, CA, USA) are the most commonly used
devices for the endoscopic and video-assisted approach (see
below). Alternatively, an endocardial approach is possible
by using cardiopulmonary bypass connected through the
groin vessels and cardioplegic arrest through a right atrial
minithoracotomy.
The surgical lesion line concept is based on the modern
knowledge of the origin of AF triggers at the connection of
the pulmonary veins to the left atrium and the modiﬁed
concepts of trigger elimination and substrate modiﬁcation.
Based on this, the key element of any ablation is a trigger
elimination by circular pulmonary vein isolation [7]. This
seems to be suﬃcient for paroxysmal AF. The lesion line
concept has to be expanded, however, to a substrate modiﬁ-
cation in more complex cases [8]. This is done by a complete
isolation of the entire posterior atrial sleeve [9], also known
as a box lesion and an ablation of the left atrial isthmus to
the posterior mitral valve ring [10]. An additional isolation
of the right atrium, which then mimics the complete lines
of the early CoxMaze III operation, can also be indicated in
selected patients and is called CoxMaze IV procedure [11].
For AF ablation performed concomitantly to cardiac
surgical procedures, devices with diﬀerent energy sources are
used. Besides the bipolar radiofrequency energy, cryoappli-
cation by means of argon or nitrous oxide and high-intensity
focused ultrasound is used [12, 13]. Depending on the
indicated atrial ablation concept the devices oﬀer diﬀerent
advantages and will be used according to the intended lesion
concept. The epicardial ablation can be performed on the
beating heart. Therefore, epicardial ablation systems will
be preferred in patients with simultaneous coronary bypass
surgery or aortic valve replacement, whereas endocardial
ablation devices are indicated predominantly during surgery
for the mitral valve, where the left atrium will be opened
in any case during the procedure. Thus, it is possible to
select the optimal ablation device according to the appro-
priate lesion concept and the concomitant cardiac surgical
procedure for an individual patient.
3.CurrentTrendsandDevices
The used ablation energy source and surgical approach
depend on the underlying type of AF and the applied con-
comitant surgical procedure. Today, most AF surgical proce-
duresareperformedasanadditionaltreatmentduringother-
wise indicated cardiac surgery. Conceptionally, an endocar-
dial approach is mostly used when opening of the left atrium
is part of the surgical procedure (i.e., mitral valve surgery in
most of the cases). In these patients cryoenergy is the energy
source of choice. In all other cases an epicardial approach
is favourable to reduce cross-clamping time and morbidity
due to blood loss and prolonged cardiopulmonary bypass
time.Fortheepicardialapproach,apulmonaryveinisolation
(PVI) is indicated in paroxysmal AF by using the diﬀerent
ablation clamps mentioned above. In more complex AF
patients, however, epicardial box lesions and even epicardial
left isthmus ablation are possible by radiofrequency energy
or high-intensity focused ultrasound.
4. RadiofrequencyEnergy
AtriCure (West Chester, OH, USA) markets the Isolator
Synergy Ablation Clamp that uses bipolar energy. The distal
end consists of two electrodes separated by an insulation.
Because the Synergy Ablation Clamp focuses the energy
directly into the contacted tissue, it can perform with higherCardiology Research and Practice 3
Figure 2:Modernradiofrequencyenergyablationdevices,AtricureIsolatorSynergyTM AblationClamp(left),MedtronicCardioblateTM BP2
(middle), and Estech CobraTM Surgical Probe (right).
Figure 3: CobraTM Revolution Bipolar Clamp (Estech, San Ramon, CA, USA).
eﬃciency than can unipolar conﬁgurations while limiting
damage to tissue that is in close proximity to the electrodes.
Medtronic (Minneapolis, MN, USA) ﬁrst developed the
Cardioblate pen. It is a pen-like device used to make point-
by-point ablations by dragging it across tissue to make a
linear lesion. Medtronic also markets three bipolar clamp
devices, all with irrigated ﬂexible jaws and an articulating
head. The Cardioblate BP has 5cm-long electrodes. Car-
dioblate BP2 has a ﬂexible neck and longer, 7cm, electrodes.
Alow-proﬁledevicewasdeveloped,CardioblateLP,featuring
a new sleek design.
In addition, Estech (San Ramon, CA, USA) oﬀers two
surgical probes: the Cobra Surgical Probe and the Cobra
Cooled Surgical Probe. Both are segmented, ﬂexible devices
withmultipleelectrodes.Thecooledprobehasinternalsaline
cooling. The Cobra Revolution Bipolar Clamp (Figure 3)
automatically adjusts power output to achieve and maintain
as a f ea n de ﬀective target temperature of >50◦C. The system
adjusts electrode output to accommodate varying tissue
depth. To maintain probe position during beating-heart
applications,theCobraAdhereprovidessuctionstabilization
totheprobedevice,whereastheCobraAdhereXLdoessofor
a minimally invasive approach.
Radiofrequency energy has been extensively used since
many years in the electrophysiological laboratory and oper-
ating theatre (Figure 2)[ 14]. Alternating current generates
electromagnetic energy of frequencies between 350 and
1000kHz. Advantages are the precise and transmural lesions
by measurement of tissue resistance, the avoidance of collat-
eral damage, and its easy usage during epicardial application
[15, 16]. Besides a potential risk of thrombogenicity of
ablation lesion lines, a full epicardial/endocardial box lesion
can be demanding [17].
5. Cryoablation
The argon-based ATS CryoMaze Surgical Ablation System
(former SurgiFrost System, CryoCath Technologies, Inc.,
Figure 4)o ﬀers a two-in-one convertible heart ablation
system with a clamp (FrostByte) and two surgical probes
(CryoMaze 7cm and 10cm). The system is versatile enough
to be used endocardially and epicardially on the beating or
arrested heart [18].
More recently, Atricure introduced a novel N2O-based
CryoICE Probe to the market (Figures 5 and 6). The device
has a 10cm malleable aluminum probe with a retractable
handle. N2O has a higher heat absorption capacity than
argon gas that requires lower gas pressures to provide
suﬃcient cooling (max. −55 to −60◦C) and no thermal
insulation. An active feedback feature at the probe/tissue
interface allows maintaining temperatures along the probe
length more consistently.
Cryoablation is, next to radiofrequency ablation (RF),
the most frequently employed alternative method to create
linear, continuous, and transmural lesions. Application of
cold by fast-expanding N2O (Boyle’s law) or by Argon or
Helium (max. −160◦C) lead to a three-step tissue injury
(freezeandthaw,inﬂammation,andﬁbrosis).Advantagesare
the beneﬁt of preserving the ﬁbrous skeleton of the heart,
the improved safety margin for ablation near the coronary
arteries or atrioventricular node, and its low incidence
of thrombus formation. Besides the relatively long time
necessaryperlesion(2to5minutes),ahigherrecurrencerate
compared to radiofrequency energy has been reported [19].
Lesions on the beating heart might be ineﬀective, and mild
esophageal lesions are described [20].
6. Microwave
The Flex 4 and Flex 10 ablation probes are the only intra-
operative, single-use devices designed to apply microwave
energy [21, 22]. Both were previously marketed by Guidant
Inc. (Boston Scientiﬁc, Natick, MA, USA). The Flex 4 has
a ﬂexible 4 cm-long sheath to ablate in increments of
2cm; the Flex 10 is 20cm long and also ablates in 2-
cm increments. The ablations are created by independently4 Cardiology Research and Practice
Figure 4: Argon-based ATS CryoMazeTM surgical ablation system.
Figure 5: N2O-based CryoICETM Probe (Atricure, Inc., West Chester, OH, USA).
activating the microwave ablation element at one or more of
thecorrespondingnumberedsegments,whichareselectedby
moving the sliding ring on the handle.
Microwave energy ablation may oﬀer the advantage of
a greater tissue penetration than radiofrequency ablation,
increasing the likelihood of a transmural lesion. In addition,
microwave heating does not cause endocardial surface
charring, which may reduce the risk of thromboembolism
[12]. However, these theoretical advantages of microwave
energy could not avoid the decline of both surgical devices.
7.LaserEnergy
MedicalCV, Inc. (Inver Grove Heights, MN, USA) markets
the AtriLaze Surgical Ablation System, which uses an 810nm
wave length, 25W diode laser. A focused, narrow beam
allows for 3mm lesions to minimize collateral damage [23].
By laser energy, precise, focused, and well-demarcated
lesions can be achieved, but a nearly perpendicular delivery
angle is required for eﬃcient energy delivery, and an
increased risk for atrial thrombus formation has been
observed [23].
8.High-IntensityFocused Ultrasound
The Epicor Ablation System (Figure 7, St. Jude Medical, Inc.,
St. Paul, MN, USA) is intended speciﬁcally for epicardial,
oﬀ-pump use and is designed to create a classic box lesion
in a single step [24]. By using the PAS system proper sizing
of the Epicor Medical UltraCinch LP device can be assured.
Seven diﬀerent sizes allow for appropriate device selection.
The UltraWandTM LP is a handheld device designed to create
linear lesions to complement the EpicorTM UltraCinch by
aiming an epicardial left atrial isthmus ablation.
Ultrasoundallowsforthedevelopmentofheatbyoscilla-
tion of aqueous tissue. Advantages are the tissue penetration
independently of the surrounding fatty tissue (within less
than 2sec), eﬀective box lesions without electrical gaps, and
the adaption to tissue thickness [25]. The endothelium is
relatively spared; hence, the risk of thrombus formation is
considered to be comparably low.Cardiology Research and Practice 5
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Figure 6: Freeze cycle of the CryoICETM Probe.
9. Results of AF Ablation
At the Leipzig Heart Center between the years 2005 are
2010 in total more than 2,400 ablations for the treatment
of atrial ﬁbrillation have been carried out (Figure 8). Due
to the new minimal-invasive procedures we did not ﬁnd
any serious ablation-associated complication. As the success
of therapy depends in particular on the etiology of atrial
ﬁbrillation, in recent years an etiology-based analysis of the
world’s largest ablation collective has been performed. For
isolated atrial ﬁbrillation a success rate of more than 90%
after one year can be expected, although this was determined
in paroxysmal AF patients who underwent no preoperative
percutaneous ablation. Due to the current patient selection
for percutaneous treatment failures a slightly lower overall
success rate may be assumed.
For 262 patients with an ablation therapy in conjunction
with coronary artery bypass surgery in our institution, the
success rate of ischemic AF etiology was the most diﬃcult
one to assess in comparison to idiopathic or valvular AF.
The rate of sinus rhythm in this group was 75% after one
year in paroxysmal AF, but only at 55% in the persistent
type of atrial ﬁbrillation. Interestingly, these patients did not
show a higher success rate when a more complex ablation
concept including a substrate modiﬁcation was chosen. As a
consequencewenowconsiderthesepatients foranoﬀ-pump
bypass surgery approach with an epicardial ablation concept
using a pulmonary vein isolation in paroxysmal AF and a full
box lesion in persistent AF types. To date, neither the success
rate nor the survival rates of surgical ablation in the diﬀerent
etiological groups (lone, valvular and ischemic AF) can be
deﬁnitively recommended on the basis of comparative trials,
even if some loose estimates exist [26, 27].
A comparable study of patients who received AF ablation
by cryoapplication during minimal-invasive mitral valve
surgery through a right lateral minithoracotomy showed
comparably better results. The lesion concept in these
patients corresponds to pulmonary vein isolation with addi-
tional isolation of the posterior atrial sleeve and a lesion to
the posterior mitral valve annulus in order to modify the
atrial substrate. In these patients, freedom from AF could
be reached in more than 70% [28]. Of utmost importance
was that for these patients also a signiﬁcant improvement of
survival was found, which was closed to that of patients with
sinus rhythm and which was signiﬁcantly better than that
of comparable patients that did not receive intraoperative
AF ablation. Thus, for the ﬁrst time it could be shown
in more than 700 mitral AF patients that ablation of
preexisting atrial ﬁbrillation was associated with a survival
advantage compared with no ablation (Figure 9). Therefore,
the ablation strategy today represents a fundamental part
during minimally invasive mitral valve surgery in patients
with preoperative AF.
10. Occlusion of the Left Atrial Appendage
10.1. Background. Patients with atrial ﬁbrillation are prone
to an at least 5- to 7-fold increased risk for developing a
thromboembolic stroke event [29]. Based on well-deﬁned
risk scores (CHADS2,C H A 2DS2-Vasc), almost all cardiac
surgical patients with AF require long-term anticoagulation.
Due to the alternative interventional occlusion of the left
atrial appendage as the main source of thromboembolic
formations a comparable event rate compared to patients
with permanent anticoagulation could be demonstrated
[30]. Therefore, in addition to AF ablation the prophylactic
occlusion of the left atrial appendage represents a treatment
option for AF patients. This is even more important in
persistent AF where, as shown above, a success rate was
limited to 55–75% only, and especially in the ﬁrst months
after AF treatment numerous short episodes of AF occur.
Thus, besides ablation, the occlusion of the atrial appendage
probably allows AF patients with a CHADS2 Score ≥ 1
the greatest protection against stroke, in particular after
discontinuation of oral anticoagulation [1].
10.2. Surgical Procedure of Atrial Appendage Occlusion. For
the surgical occlusion of the atrial appendage several options
are available. These include an endocardial occlusion of
the oriﬁce of the left atrial appendage to the left atrium,
the resection/amputation of the appendage with following
double-row stitches, or epicardial occlusion at its base while
leaving the appendage in situ. The latter is possible by
surgical purse-string sutures, but also, the use of endoloop
systems, staplers, and more recently clips (Figure 10). The
use of endoloops, staplers, or clips oﬀe r sa d v a n t a g e si n
particular within the scope of videoscopic and minimal-
invasive ablation procedures. Due to the diﬀerent sizes and
variable anatomy of the left atrial appendage, diﬀerent sizes
of staplers and clips are available. For all procedures it is6 Cardiology Research and Practice
(a) (b) (c)
Figure 7: Modern high-intensity focused ultrasound (HIFU) ablation device, EpicorTM System Console (a), EpicorTM UltraWand LP (b)
and medical UltraCinch LP ablation device (c). LP: low proﬁle.
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Figure 10: Surgical procedure of atrial appendage occlusion by the use of endoloop systems, staplers, or clips.
important to look for a gentle approach, because the left
atrial appendage is sometimes very thin, and injuries can
occur easily.
10.3. Gillinov-Cosgrove LAA Exclusion System. The AtriClip
(Atricure, Inc., West Chester, OH, USA) is developed for
the occlusion of the left atrial appendage, under direct visu-
alization, in conjunction with other open cardiac surgical
procedures. The AtriClip is available in various sizes, can
easily be repositioned prior to suture release, and closes as
tissue is compressed. While the oriﬁce is permanently sealed
with a low compression force between 2 to 8psi, the tissue is
fully absorbed.
10.4. Results of Atrial Appendage Occlusion. B a s e do ns e v e r a l
observational studies a prophylactic occlusion of the left
atrial appendage seems suitable to avoid subsequent strokes
in the scope of cardiac surgery [31]. In addition, it could be
shown based on a study of 137 patients that in comparison
of excision/resection against the exclusion by sutures or
staplers, the excision represented the more eﬀective therapy
with respect to the presence of residual niches at the base
of the atrial appendage [32]. The extent to which this can
be transferred to today’s exclusion systems is unknown, but
current data, however, suggest a better success with modern
exclusion systems [6]. In either case the optimal position
and the occlusion has to be controlled by intraoperative
transesophageal echocardiography.
10.5. Summary. The introduction of new AF ablation tech-
nologies has revolutionized the surgical therapy of atrial
ﬁbrillation. Atrial ﬁbrillation can be found as a comorbidity
in an increasing number of cardiac surgical patients due
to increasing patient age having an indication for coronary
artery bypass or valve surgery.
While modern surgical ablation concepts are based on
the origin of AF triggers and the modiﬁed concepts of
trigger elimination and substrate modiﬁcation, new minimal
invasive techniques allow for short operation times, rapid
recovery, and short hospital stays of a few days. Epicardial
ablation systems will be preferred in patients with simulta-
neous coronary bypass surgery or aortic valve replacement,
whereas endocardial ablation devices are indicated predom-
inantly during surgery for the mitral valve, where the left
atrium will be opened. In addition, novel devices designed
speciﬁcally for minimally invasive epicardial exclusion of the
left atrial appendage will broaden the range of treatment
options available.
Surgical AF ablation is a procedure in evolution with a
variety of incisions, lesion sets, and energy modalities in use.
To optimise its potential, further studies of their eﬃcacy and
safety will guide their future development.
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